Lite Strategy (LITS) Cash from Operations (2010 - 2026)
Lite Strategy (LITS) posted quarterly Cash from Operations of 1520000.0 for Q1 2026, up 53.47% year-over-year from 990394.89 in Q1 2025, and up 21.2% quarter-over-quarter from 1929000.0 in Q4 2025.
Lite Strategy (LITS) Cash from Operations (2010 - 2026) Analysis & Trends
Lite Strategy's Cash from Operations history runs 17 years deep, the most recent figure standing at 1520000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 53.47% year-over-year to 1520000.0; the TTM figure through Mar 2026 stood at 10418000.0 (up 71.36% YoY), while the FY2025 annual figure was 20844000.0, up 58.7% from the prior year.
- Cash from Operations for Q1 2026 stood at 1520000.0, up from 1929000.0 in the prior quarter.
- The five-year high for Cash from Operations was 1520000.0 in Q1 2026, with the low at 18491000.0 in Q3 2023.
- The 5-year median for Cash from Operations is 11302000.0 (2023), against an average of 9659823.53.
- The sharpest annual moves came in 2022 and 2025: Cash from Operations slumped 91.45% in 2022, then surged 86.33% in 2025.
- Lite Strategy's Cash from Operations stood at 14270000.0 in 2022, then rose by 22.53% to 11055000.0 in 2023, then surged by 66.84% to 3666000.0 in 2024, then surged by 47.38% to 1929000.0 in 2025, then advanced by 21.2% to 1520000.0 in 2026.
- Business Quant data shows LITS's Cash from Operations at 1520000.0 in Q1 2026, 1929000.0 in Q4 2025, and 4508000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | -1.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.52 Mn |
| Mar 31, 2026 | -1.52 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Dec 31, 2025 | -1.93 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Sep 30, 2025 | -4.51 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Jun 30, 2025 | -2.46 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Mar 31, 2025 | -3.27 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Dec 31, 2024 | -3.67 Mn |
| Sep 30, 2024 | -11.45 Mn |
| Sep 30, 2024 | -11.45 Mn |
| Jun 30, 2024 | -18.00 Mn |
| Jun 30, 2024 | -18.00 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Mar 31, 2024 | -2.93 Mn |
| Dec 31, 2023 | -11.06 Mn |
| Dec 31, 2023 | -11.06 Mn |